Startseite>>Signaling Pathways>> Endocrinology and Hormones>> GnRH>>Cetrorelix Acetate (SB-075 acetate)

Cetrorelix Acetate (SB-075 acetate) (Synonyms: SB-75)

Katalog-Nr.GC33467

Cetrorelix-Acetat (SB-075-Acetat) (SB-75-Acetat) ist ein wirksamer Antagonist des Gonadotropin-Releasing-Hormon (GnRH)-Rezeptors mit einem IC50 von 1,21 nM.

Products are for research use only. Not for human use. We do not sell to patients.

Cetrorelix Acetate (SB-075 acetate) Chemische Struktur

Cas No.: 145672-81-7

Größe Preis Lagerbestand Menge
1mg
50,00 $
Auf Lager
5mg
91,00 $
Auf Lager
10mg
151,00 $
Auf Lager
25mg
304,00 $
Auf Lager
50mg
441,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cetrorelix Acetate is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM.

Cetrorelix Acetate inhibits growth of ES-2 cell line at 1000 ng/ml. Cetrorelix Acetate has comparable antiproliferative effects as GnRH-I agonists indicating that the dichotomy of GnRH-I agonists and antagonists might not apply to the GnRH-I system in cancer cells[2].

[1]. Beckers T et al. Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23. [2]. Gründker C et al. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003 Oct 7;1:65.

Bewertungen

Review for Cetrorelix Acetate (SB-075 acetate)

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cetrorelix Acetate (SB-075 acetate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.